Egzeon Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 07-12-2024
- Paid Up Capital ₹ 0.60 M
as on 07-12-2024
- Company Age 13 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.80 M
as on 07-12-2024
- Revenue %
(FY 2017)
- Ebitda
- Net Worth
- Total Assets %
(FY 2017)
About Egzeon Pharmaceuticals
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.60 M.
The company currently has active open charges totaling ₹1.80 M.
Ankur Arora and Rita Arora serve as directors at the Company.
- CIN/LLPIN
U24232HR2011PTC043500
- Company No.
043500
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jul 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Ambala, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Egzeon Pharmaceuticals Private Limited offer?
Egzeon Pharmaceuticals Private Limited offers a wide range of products and services, including Infusion Syringes & Supplies, Disposable Cannulas, Industrial Uniforms & Safety Wear, Reusable Respirator, Disinfection Equipment & Machines, Fumigation Machine, Ear Plugs, Bandages & Dressing Disposables, Hospital Dressings, Work Boots and Safety Shoes.
Who are the key members and board of directors at Egzeon Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ankur Arora  | Director | 09-Nov-2015 | Current |
| Rita Arora | Director | 02-Apr-2019 | Current |
Financial Performance of Egzeon Pharmaceuticals.
Egzeon Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Egzeon Pharmaceuticals?
In 2017, Egzeon Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 May 2019 | ₹1.80 M | Open |
How Many Employees Work at Egzeon Pharmaceuticals?
Unlock and access historical data on people associated with Egzeon Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Egzeon Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Egzeon Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
